Task Force Report on Antiphospholipid Syndrome Clinical Research View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2012-03-20

AUTHORS

Doruk Erkan , Silvia S. Pierangeli , Michael D. Lockshin

ABSTRACT

The Antiphospholipid Syndrome (APS) Clinical Research Task Force (CRTF) was one of the six task forces developed by the 13th International Congress on Antiphospholipid Antibodies (aPL) organization committee with the purpose of: (a) evaluating the limitations of APS clinical research and developing guidelines for researchers to help improve the quality of APS research; and (b) prioritizing the ideas for a well-designed multicenter clinical trial and discussing the pragmatics of getting such a trial done. Following a systematic working algorithm, the task force identified five major issues that impede APS clinical research and the ability to develop evidence-based recommendations for the management of aPL positive patients: (1) aPL detection has been based on partially or nonstandardized tests, and clinical (and basic) APS research studies have included patients with heterogeneous aPL profiles with different clinical event risks; (2) clinical (and basic) APS research studies have included a heterogeneous group of patients with different aPL-related manifestations (some controversial); (3) thrombosis and/or pregnancy risk stratification and quantification are rarely incorporated in APS clinical research; (4) most APS clinical studies include patients with single positive aPL results and/or low-titer aPL ELISA results; furthermore, study designs are mostly retrospective and not population based, with limited number of prospective and/or controlled population studies; and (5) lack of the understanding the particular mechanisms of aPL-mediated clinical events limits the optimal clinical study design. The task force recommended that there is an urgent need for a true International collaborative approach to design and conduct well-designed prospective large-scale multicenter clinical trials of patients with persistent and clinically significant aPL profiles. Following the final recommendation of APS CRTF, an international collaborative working meeting took place in Miami (Nov 2–4, 2010) that resulted in the formation of a clinical trial research alliance entitled: AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (“APS ACTION”). More... »

PAGES

247-257

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-4614-3194-7_17

DOI

http://dx.doi.org/10.1007/978-1-4614-3194-7_17

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1009781957


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medical College of Cornell University, 535 E70th Street, 10021, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.5386.8", 
          "name": [
            "The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medical College of Cornell University, 535 E70th Street, 10021, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Erkan", 
        "givenName": "Doruk", 
        "id": "sg:person.0706272321.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706272321.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Rheumatology, Department of Internal Medicine, Microbiology and Pathology, University of Texas Medical Branch, Galveston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.176731.5", 
          "name": [
            "Division of Rheumatology, Department of Internal Medicine, Microbiology and Pathology, University of Texas Medical Branch, Galveston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pierangeli", 
        "givenName": "Silvia S.", 
        "id": "sg:person.01026125740.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026125740.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medical College of Cornell University, 535 E70th Street, 10021, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.5386.8", 
          "name": [
            "The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medical College of Cornell University, 535 E70th Street, 10021, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lockshin", 
        "givenName": "Michael D.", 
        "id": "sg:person.01215046705.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215046705.41"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2012-03-20", 
    "datePublishedReg": "2012-03-20", 
    "description": "The Antiphospholipid Syndrome (APS) Clinical Research Task Force (CRTF) was one of the six task forces developed by the 13th International Congress on Antiphospholipid Antibodies (aPL) organization committee with the purpose of: (a) evaluating the limitations of APS clinical research and developing guidelines for researchers to help improve the quality of APS research; and (b) prioritizing the ideas for a well-designed multicenter clinical trial and discussing the pragmatics of getting such a trial done. Following a systematic working algorithm, the task force identified five major issues that impede APS clinical research and the ability to develop evidence-based recommendations for the management of aPL positive patients: (1) aPL detection has been based on partially or nonstandardized tests, and clinical (and basic) APS research studies have included patients with heterogeneous aPL profiles with different clinical event risks; (2) clinical (and basic) APS research studies have included a heterogeneous group of patients with different aPL-related manifestations (some controversial); (3) thrombosis and/or pregnancy risk stratification and quantification are rarely incorporated in APS clinical research; (4) most APS clinical studies include patients with single positive aPL results and/or low-titer aPL ELISA results; furthermore, study designs are mostly retrospective and not population based, with limited number of prospective and/or controlled population studies; and (5) lack of the understanding the particular mechanisms of aPL-mediated clinical events limits the optimal clinical study design. The task force recommended that there is an urgent need for a true International collaborative approach to design and conduct well-designed prospective large-scale multicenter clinical trials of patients with persistent and clinically significant aPL profiles. Following the final recommendation of APS CRTF, an international collaborative working meeting took place in Miami (Nov 2\u20134, 2010) that resulted in the formation of a clinical trial research alliance entitled: AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (\u201cAPS ACTION\u201d).", 
    "editor": [
      {
        "familyName": "Erkan", 
        "givenName": "Doruk", 
        "type": "Person"
      }, 
      {
        "familyName": "Pierangeli", 
        "givenName": "Silvia S.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-4614-3194-7_17", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-4614-3193-0", 
        "978-1-4614-3194-7"
      ], 
      "name": "Antiphospholipid Syndrome", 
      "type": "Book"
    }, 
    "keywords": [
      "multicenter clinical trial", 
      "clinical trials", 
      "clinical research", 
      "large-scale multicenter clinical trials", 
      "evidence-based recommendations", 
      "study design", 
      "aPL positive patients", 
      "Task Force", 
      "AntiPhospholipid Syndrome Alliance", 
      "clinical event risks", 
      "clinical study design", 
      "APS research", 
      "aPL profile", 
      "positive patients", 
      "risk stratification", 
      "clinical events", 
      "clinical studies", 
      "patients", 
      "aPL results", 
      "event risk", 
      "heterogeneous group", 
      "trials", 
      "different aPL", 
      "Task Force Report", 
      "population studies", 
      "international collaborative approach", 
      "Research Task Force", 
      "ELISA results", 
      "Force Report", 
      "research studies", 
      "final recommendations", 
      "urgent need", 
      "APL", 
      "thrombosis", 
      "study", 
      "manifestations", 
      "recommendations", 
      "risk", 
      "Research Alliance", 
      "limited number", 
      "collaborative approach", 
      "report", 
      "guidelines", 
      "organization committee", 
      "working algorithm", 
      "group", 
      "population", 
      "International Congress", 
      "profile", 
      "stratification", 
      "management", 
      "particular mechanism", 
      "Committee", 
      "lack", 
      "test", 
      "events", 
      "Miami", 
      "results", 
      "research", 
      "mechanism", 
      "meeting", 
      "need", 
      "purpose", 
      "ability", 
      "quality", 
      "number", 
      "detection", 
      "international networking", 
      "quantification", 
      "understanding", 
      "limitations", 
      "major issue", 
      "alliance", 
      "design", 
      "formation", 
      "force", 
      "issues", 
      "approach", 
      "Congress", 
      "place", 
      "researchers", 
      "pragmatics", 
      "idea", 
      "algorithm", 
      "networking", 
      "Antiphospholipid Syndrome (APS) Clinical Research Task Force", 
      "Syndrome (APS) Clinical Research Task Force", 
      "CRTF", 
      "Antiphospholipid Antibodies (aPL) organization committee", 
      "Antibodies (aPL) organization committee", 
      "APS clinical research", 
      "systematic working algorithm", 
      "clinical (and basic) APS research studies", 
      "APS research studies", 
      "heterogeneous aPL profiles", 
      "different clinical event risks", 
      "pregnancy risk stratification", 
      "most APS clinical studies", 
      "APS clinical studies", 
      "single positive aPL results", 
      "positive aPL results", 
      "low-titer aPL ELISA results", 
      "aPL ELISA results", 
      "optimal clinical study design", 
      "true International collaborative approach", 
      "prospective large-scale multicenter clinical trials", 
      "APS CRTF", 
      "clinical trial research alliance", 
      "trial research alliance", 
      "Syndrome Alliance", 
      "Antiphospholipid Syndrome Clinical Research", 
      "Syndrome Clinical Research"
    ], 
    "name": "Task Force Report on Antiphospholipid Syndrome Clinical Research", 
    "pagination": "247-257", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1009781957"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-4614-3194-7_17"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-4614-3194-7_17", 
      "https://app.dimensions.ai/details/publication/pub.1009781957"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2021-12-01T20:09", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/chapter/chapter_414.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-4614-3194-7_17"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-4614-3194-7_17'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-4614-3194-7_17'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-4614-3194-7_17'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-4614-3194-7_17'


 

This table displays all metadata directly associated to this object as RDF triples.

194 TRIPLES      23 PREDICATES      137 URIs      130 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-4614-3194-7_17 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Na1542a7184974c65ad2ef7ff4f1fc1d1
4 schema:datePublished 2012-03-20
5 schema:datePublishedReg 2012-03-20
6 schema:description The Antiphospholipid Syndrome (APS) Clinical Research Task Force (CRTF) was one of the six task forces developed by the 13th International Congress on Antiphospholipid Antibodies (aPL) organization committee with the purpose of: (a) evaluating the limitations of APS clinical research and developing guidelines for researchers to help improve the quality of APS research; and (b) prioritizing the ideas for a well-designed multicenter clinical trial and discussing the pragmatics of getting such a trial done. Following a systematic working algorithm, the task force identified five major issues that impede APS clinical research and the ability to develop evidence-based recommendations for the management of aPL positive patients: (1) aPL detection has been based on partially or nonstandardized tests, and clinical (and basic) APS research studies have included patients with heterogeneous aPL profiles with different clinical event risks; (2) clinical (and basic) APS research studies have included a heterogeneous group of patients with different aPL-related manifestations (some controversial); (3) thrombosis and/or pregnancy risk stratification and quantification are rarely incorporated in APS clinical research; (4) most APS clinical studies include patients with single positive aPL results and/or low-titer aPL ELISA results; furthermore, study designs are mostly retrospective and not population based, with limited number of prospective and/or controlled population studies; and (5) lack of the understanding the particular mechanisms of aPL-mediated clinical events limits the optimal clinical study design. The task force recommended that there is an urgent need for a true International collaborative approach to design and conduct well-designed prospective large-scale multicenter clinical trials of patients with persistent and clinically significant aPL profiles. Following the final recommendation of APS CRTF, an international collaborative working meeting took place in Miami (Nov 2–4, 2010) that resulted in the formation of a clinical trial research alliance entitled: AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (“APS ACTION”).
7 schema:editor N38818baa10844d03a7d756a410e618ef
8 schema:genre chapter
9 schema:inLanguage en
10 schema:isAccessibleForFree false
11 schema:isPartOf N74583e49d95a44dbbcb22aa91fcd170b
12 schema:keywords APL
13 APS CRTF
14 APS clinical research
15 APS clinical studies
16 APS research
17 APS research studies
18 AntiPhospholipid Syndrome Alliance
19 Antibodies (aPL) organization committee
20 Antiphospholipid Antibodies (aPL) organization committee
21 Antiphospholipid Syndrome (APS) Clinical Research Task Force
22 Antiphospholipid Syndrome Clinical Research
23 CRTF
24 Committee
25 Congress
26 ELISA results
27 Force Report
28 International Congress
29 Miami
30 Research Alliance
31 Research Task Force
32 Syndrome (APS) Clinical Research Task Force
33 Syndrome Alliance
34 Syndrome Clinical Research
35 Task Force
36 Task Force Report
37 aPL ELISA results
38 aPL positive patients
39 aPL profile
40 aPL results
41 ability
42 algorithm
43 alliance
44 approach
45 clinical (and basic) APS research studies
46 clinical event risks
47 clinical events
48 clinical research
49 clinical studies
50 clinical study design
51 clinical trial research alliance
52 clinical trials
53 collaborative approach
54 design
55 detection
56 different aPL
57 different clinical event risks
58 event risk
59 events
60 evidence-based recommendations
61 final recommendations
62 force
63 formation
64 group
65 guidelines
66 heterogeneous aPL profiles
67 heterogeneous group
68 idea
69 international collaborative approach
70 international networking
71 issues
72 lack
73 large-scale multicenter clinical trials
74 limitations
75 limited number
76 low-titer aPL ELISA results
77 major issue
78 management
79 manifestations
80 mechanism
81 meeting
82 most APS clinical studies
83 multicenter clinical trial
84 need
85 networking
86 number
87 optimal clinical study design
88 organization committee
89 particular mechanism
90 patients
91 place
92 population
93 population studies
94 positive aPL results
95 positive patients
96 pragmatics
97 pregnancy risk stratification
98 profile
99 prospective large-scale multicenter clinical trials
100 purpose
101 quality
102 quantification
103 recommendations
104 report
105 research
106 research studies
107 researchers
108 results
109 risk
110 risk stratification
111 single positive aPL results
112 stratification
113 study
114 study design
115 systematic working algorithm
116 test
117 thrombosis
118 trial research alliance
119 trials
120 true International collaborative approach
121 understanding
122 urgent need
123 working algorithm
124 schema:name Task Force Report on Antiphospholipid Syndrome Clinical Research
125 schema:pagination 247-257
126 schema:productId N6e78822df4294665a255125c8609487a
127 Nc205112fadd04d2cac9075c8a14995cd
128 schema:publisher Nf4f057b6b9ed4c57bebcedf5f89d2642
129 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009781957
130 https://doi.org/10.1007/978-1-4614-3194-7_17
131 schema:sdDatePublished 2021-12-01T20:09
132 schema:sdLicense https://scigraph.springernature.com/explorer/license/
133 schema:sdPublisher N9fa52367ca6c4ca78c8128988390f29c
134 schema:url https://doi.org/10.1007/978-1-4614-3194-7_17
135 sgo:license sg:explorer/license/
136 sgo:sdDataset chapters
137 rdf:type schema:Chapter
138 N313519383492436c8867a960c3073c3a schema:familyName Erkan
139 schema:givenName Doruk
140 rdf:type schema:Person
141 N38818baa10844d03a7d756a410e618ef rdf:first N313519383492436c8867a960c3073c3a
142 rdf:rest N9c5e6753ec184216a063faa062006458
143 N45fd47ef89494f75a7bd60f2932cf105 rdf:first sg:person.01215046705.41
144 rdf:rest rdf:nil
145 N6e78822df4294665a255125c8609487a schema:name dimensions_id
146 schema:value pub.1009781957
147 rdf:type schema:PropertyValue
148 N74583e49d95a44dbbcb22aa91fcd170b schema:isbn 978-1-4614-3193-0
149 978-1-4614-3194-7
150 schema:name Antiphospholipid Syndrome
151 rdf:type schema:Book
152 N9bdcb1f25f6145ef885d3db4c4053f81 rdf:first sg:person.01026125740.15
153 rdf:rest N45fd47ef89494f75a7bd60f2932cf105
154 N9c5e6753ec184216a063faa062006458 rdf:first Nbf5c4da933704a9cb6097d408ba1dce8
155 rdf:rest rdf:nil
156 N9fa52367ca6c4ca78c8128988390f29c schema:name Springer Nature - SN SciGraph project
157 rdf:type schema:Organization
158 Na1542a7184974c65ad2ef7ff4f1fc1d1 rdf:first sg:person.0706272321.25
159 rdf:rest N9bdcb1f25f6145ef885d3db4c4053f81
160 Nbf5c4da933704a9cb6097d408ba1dce8 schema:familyName Pierangeli
161 schema:givenName Silvia S.
162 rdf:type schema:Person
163 Nc205112fadd04d2cac9075c8a14995cd schema:name doi
164 schema:value 10.1007/978-1-4614-3194-7_17
165 rdf:type schema:PropertyValue
166 Nf4f057b6b9ed4c57bebcedf5f89d2642 schema:name Springer Nature
167 rdf:type schema:Organisation
168 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
169 schema:name Medical and Health Sciences
170 rdf:type schema:DefinedTerm
171 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
172 schema:name Clinical Sciences
173 rdf:type schema:DefinedTerm
174 sg:person.01026125740.15 schema:affiliation grid-institutes:grid.176731.5
175 schema:familyName Pierangeli
176 schema:givenName Silvia S.
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026125740.15
178 rdf:type schema:Person
179 sg:person.01215046705.41 schema:affiliation grid-institutes:grid.5386.8
180 schema:familyName Lockshin
181 schema:givenName Michael D.
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215046705.41
183 rdf:type schema:Person
184 sg:person.0706272321.25 schema:affiliation grid-institutes:grid.5386.8
185 schema:familyName Erkan
186 schema:givenName Doruk
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706272321.25
188 rdf:type schema:Person
189 grid-institutes:grid.176731.5 schema:alternateName Division of Rheumatology, Department of Internal Medicine, Microbiology and Pathology, University of Texas Medical Branch, Galveston, TX, USA
190 schema:name Division of Rheumatology, Department of Internal Medicine, Microbiology and Pathology, University of Texas Medical Branch, Galveston, TX, USA
191 rdf:type schema:Organization
192 grid-institutes:grid.5386.8 schema:alternateName The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medical College of Cornell University, 535 E70th Street, 10021, New York, NY, USA
193 schema:name The Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medical College of Cornell University, 535 E70th Street, 10021, New York, NY, USA
194 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...